Cargando…
TRONARTO: A Randomized, Placebo-Controlled Study of Tiotropium/Olodaterol Delivered via Soft Mist Inhaler in COPD Patients Stratified by Peak Inspiratory Flow
BACKGROUND: Inhaled bronchodilator therapy is currently the mainstay of treatment for patients with chronic obstructive pulmonary disease (COPD). Some inhalers require patients to achieve certain inhalation efforts either to activate the device or to deliver medication to the site of action. For dry...
Autores principales: | Mahler, Donald A, Ludwig-Sengpiel, Andrea, Ferguson, Gary T, de la Hoz, Alberto, Ritz, John, Shaikh, Asif, Watz, Henrik |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8414074/ https://www.ncbi.nlm.nih.gov/pubmed/34511891 http://dx.doi.org/10.2147/COPD.S324467 |
Ejemplares similares
-
Clinical Implications of Peak Inspiratory Flow in COPD: Post Hoc Analyses of the TRONARTO Study
por: Mahler, Donald A, et al.
Publicado: (2023) -
Effects of combined tiotropium/olodaterol on inspiratory capacity and exercise endurance in COPD
por: O'Donnell, Denis E., et al.
Publicado: (2017) -
Long-term safety of tiotropium delivered by Respimat(®) SoftMist™ Inhaler: patient selection and special considerations
por: Tan, Ching Kuo, et al.
Publicado: (2016) -
Tiotropium/olodaterol versus tiotropium in Japanese patients with COPD: results from the DYNAGITO study
por: Ichinose, Masakazu, et al.
Publicado: (2018) -
Tiotropium/Olodaterol: A Review in COPD
por: Blair, Hannah A.
Publicado: (2019)